Proprotein convertases are proteases that have been implicated in the activation of a wide variety of proteins. These proteins are generally synthesised as precursor proteins and require limited proteolysis for conversion into their mature bioactive counterparts. Many of these proteins, including metalloproteases, growth factors and their receptors or adhesion molecules, have been shown to facilitate tumour formation and progression. Hence, this review will focus on the proprotein convertase furin and its role in cancer. The expression of furin has been confirmed in a large spectrum of cancers such as head and neck squamous cell carcinoma, breast cancer and rhabdomyosarcoma. Functional studies modulating furin activity uncovered its importance for the processing of many cancer-related substrates and strongly indicate that high furin activity promotes the malignant phenotype of cancer cells. In this review, we summarise the expression and function of furin in different cancer types, discuss its role in processing cancer-related proproteins and give examples of potential therapeutic approaches that take advantage of the proteolytic activity of furin in cancer cells.
Proprotein convertases (PCs) are proteases of the subtilase family that process proproteins through limited proteolysis and convert them into bioactive proteins and peptides. Two PCs, MBTPS1 and PCSK9, cleave after non-basic residues and are involved in cholesterol metabolism and low density lipoprotein receptor (LDLR) recycling, respectively. The other seven mammalian PCs, PCSK1, PCSK2, furin, PCSK4, PCSK5, PCSK6 and PCSK7, cleave proproteins at paired basic residues. These furin-like PCs cleave a variety of precursor proteins within the secretory pathway, including neuropeptides, hormones, growth factors and their receptors, adhesion molecule, bacterial toxins and viral glycoproteins. 1 As a result, a deregulation of furin-like PC activity has been associated with pathological conditions like endocrinopathies, 2 Alzheimer's disease 3 and cancer. 4, 5 An overview of gene symbols, protein names and alternative names of the proprotein convertases can be found in Table 1 and their tissue distribution and subcellular localisation patterns are summarised in Table 2 .
Furin is a ubiquitously expressed calcium-dependent protease that is expressed in all vertebrates and many invertebrates. 6 It is expressed as a 794 amino acid zymogen that undergoes two autocatalytic cleavage steps before it becomes fully active. 7 Furin has a strong preference for basic amino acids and processes substrates at the consensus cleavage site R-X-K/R-R#, whereby X represents any amino acid but cysteine and rarely proline. 8 In order to elucidate the stringent cleavage preference of furin and to improve design of inhibitors, several groups crystallised the structure of furin. [9] [10] [11] [12] For instance, published crystal structures of mouse and human furin in complex with covalent or competitive inhibitors, respectively, highlight the presence of highly charge-complementary pockets within the active site, explaining the stringent requirement for basic amino acids in the cleavage site. [9] [10] [11] Expression, intracellular localisation and activity of furin in cancer cells appear to be regulated by different factors. For instance, hypoxic conditions were reported to upregulate furin expression, 13, 14 whereby others suggested that tissue hypoxia in vivo might have no impact on transcriptional levels of furin. 15 A recent study indicates that a negative feedback loop exists as furin and PCSK7 might interfere with HIF1a translation. 16 Hypoxia further favours relocalisation of intracellular furin to the cell surface, thereby increasing cancer cell invasion. 17 Furin expression under varying conditions can also be regulated by other factors such as the transforming growth factor b1 (TGFb1), 18, 19 thyroid hormone signalling 20 or prostaglandinendoperoxide synthase 2 (PTGS2). 21 Enhanced expression of furin was confirmed in various cancer types and furin activity promotes many cancer-related processes like cell proliferation, migration and invasion or vascularisation. Hence, in this review we will summarise published studies investigating the expression and the function of furin in cancer. For this part we conducted a PubMed search with the search term "(furin[Title/Abstract]) AND cancer" and considered all 372 publications (last updated: 25 th of January 2017). We further aim to give a general overview of cancer-related proproteins that are processed by furin. Finally, we will highlight a few chosen approaches that implement furin as a tool for cancer therapy.
Furin Promotes Tumour Progression
Over the last 20 years many studies have examined the expression of furin in a variety of cancers (Table 3) . In some cases, expression of furin correlated with aggressiveness and increased expression was proposed as a marker for advanced or high-grade disease. Furthermore, modulation of PC activity has helped to decipher the role of furin and other PCs in diverse processes involved in carcinogenesis and cancer progression. The most common approaches adopted are (i) ectopic overexpression of furin, (ii) silencing of furin expression through use of specific siRNA or shRNA, (iii) ectopic expression of furin's inhibitory prosegment, (iv) ectopic expression or application of the pan-PC inhibitor a1-PDX (PDX) 22 and (v) application of other pan-PC inhibitors such as dec-RVKR-CMK (CMK). 23 In the following section we will discuss in detail the involvement of furin in different types of cancer, thereby highlighting expression studies, in vitro and in vivo furin activity modulating studies including overexpression and inhibition studies and indicate known mechanisms of furin expression and activity regulation.
Lung carcinomas
Neoplasias of the lung were among the first cancers investigated for PC activity. In the late 1980s Schalken et al. observed a selective and strong furin mRNA expression in lung cancer tissues derived from non-small cell lung cancer (NSCLC), but not in those derived from small cell lung cancer (SCLC). 24 Other studies detected high furin mRNA levels in lung squamous cell carcinomas and adenocarcinomas of the lungs. [25] [26] [27] Moreover, furin mRNA and protein levels appeared to correlate with the invasive potential of NSCLC cell lines 28 and furin protein expression was found in the majority of invasive squamous cell carcinomas (SCC) of the lung. 29 Elevated levels of furin in NSCLC cell lines likely relies on the activity of PTGS2 and the transcription factor E2F1, as interference with either one decreases furin activity. 21 Functional studies showed that inhibition of furin activity, either through genetic silencing or through application of the inhibitors PDX or CMK, decreases processing of the insulin-like growth factor 1 receptor (IGF1R), cell proliferation, in vitro migration and invasion abilities, as well as in vivo tumour growth. 26, 30 These observations indicate that furin expression is not only a potential marker, 27 but also a potential therapeutic target for lung carcinomas.
Head and neck squamous cell carcinomas
The role of furin in cellular processes has been extensively studied in head and neck squamous cell carcinoma (HNSCC). In 2001, Bassi et al. investigated mRNA and protein levels of furin in HNSCC primary tumours and cell lines and found a correlation between furin levels and aggressiveness in HNSCC. 28 They further observed higher levels of furin and matrix metalloproteinase 14 (MMP14 aka membrane type 1 matrix metalloprotease or MT1-MMP) in metastasising tumours. 28 Functional studies helped to decipher furin's role in the malignant phenotype of HNSCC cells. Different studies, through overexpression of furin or inhibition of the protease, for example, through use of the inhibitors PDX, CMK and of furin's prosegment, showed that furin activity promotes cell proliferation, tumourigenicity and invasiveness in vitro and in vivo. [31] [32] [33] Further investigations indicated that furin activity is required to process cancer-related proproteins in HNSCC, including TGFb, MMP14, IGF1R and vascular endothelial growth factor C (VEGF-C). [31] [32] [33] Squamous cell carcinomas of the oral cavity and oesophagus and laryngeal cancer Almost 15 years ago Lopez de Cicco et al. examined furin protein expression in SCC tissue samples of the oral cavity and oesophagus and confirmed furin expression in approximately 90% of oral SCC and in all SCC of the oesophagus investigated. 29 Furin was eventually proposed as a marker of tumour progression in oral tongue SCC as furin and VEGF-C expression is considerably higher in preinvasive and invasive neoplasia. 34 Furthermore, furin expression correlates with VEGF-C processing in oral tongue SCC cell lines and with increased micro vessel density in precursor lesions and SCC of the tongue, as determined by immunohistochemistry in human tongue sections. 34 The role of furin in SCC progression had been indicated in a previous study in which Aznavoorian et al. showed that MMP14-mediated collagen degradation by SCC cells is dependent on furin activity and on its ability to convert MMP14 zymogen into its active form in vitro. 35 In a recent publication, Lee et al. examined the expression of furin in laryngeal cancer biopsies and cell lines pre-and post-radiation and found that radiotherapy is associated with elevated furin levels. 36 Furthermore, furin inhibition by application of CMK decreased MMP14 expression and invasiveness in laryngeal cancer cells in vitro. 36 
Breast cancer
Furin mRNA expression was confirmed in 30 breast tumour tissues and various breast cancer cell lines. 37 Despite a lack of correlation between levels of furin and oestrogen receptor in tissue samples, 37 overexpression of either PCSK1 or furin confers an increased dependency on oestrogen as well as anti-oestrogen resistance in breast cancer cell lines in vitro. 38 Interestingly, inhibition of furin through expression of its prosegment reduced the invasive phenotype of breast cancer cell lines in vitro, whereas expression of the prosegment of PCSK6 had the inverse effect, pointing at opposing roles of furin and PCSK6 in breast cancer motility and invasiveness. 39 In another in vitro study furin inhibition was used to decrease MMP14 activity in breast cancer cells, which resulted in changed levels of MMP2 and MMP9, 40 indicating a potential link between furin activity, MMP expression and motility in breast cancer cells. Additionally, Scamuffa et al. showed that overexpression of the inhibitory prosegment of furin in MDA-MB-231 cells results in impaired processing of the substrates platelet-derived growth factor A (PDGF-A aka PDGF-1) and IGF1R and delayed tumour growth in vivo. 41 Endometrial, cervical and ovarian cancer Singh et al. investigated the expression level of furin-like PCs in post-menopausal endometrial cancer cell lines and biopsies and found that furin is the most consistently expressed PC in endometrial cancer cell lines. 42 Furthermore, furin was the only PC showing increased levels in endometrial cancer biopsies as compared to control tissue. Thus, monitoring PC activity in uterine lavage samples 42, 43 or in endocervical swabs 44 were proposed as non-invasive diagnostic tools for endometrial cancer as in both cases PC activity was notably higher in patient samples than in healthy controls.
In cervical cancer cells it has been shown that stimulation of the cells with the cytokine osteopontin leads to NF-jBdependent expression of furin, which is associated with enhanced motility in vitro and tumour growth in vivo. 45 Moreover, increased expression of osteopontin and furin correlates with cervical cancer progression. 45 Two studies confirmed furin expression in the different cancerous stages of ovarian cancer, including primary tumour, ascites and metastases, and found a correlation between furin expression and poor prognosis for ovarian cancer patients. 46, 47 However, another study indicates that furin and PCSK7 expression in primary ovarian cancer cultures is comparable to that in ovarian surface epithelium cultures. 48 To date, functional evaluation of furin in ovarian cancer is sparse. To our knowledge, Longuesp ee et al. are the only ones who made an attempt to functionally evaluate furin in ovarian cancer. However, their in vitro study is limited to downregulation of furin by shRNA in the ovarian cancer cell line SKOV3, which had no significant effect on cell proliferation. 47 Further in vitro and in vivo studies will be required to decipher in depth the role of furin and other PCs in ovarian cancer.
Cancers of the gastro-intestinal tract
Furin expression was observed in most gastric cancer tissues and cell lines. 49 
Sarcomas
In recent studies we have shown that furin is expressed in over 86% of paediatric rhabdomyosarcoma (RMS) tumours. Modulation of furin activity in different RMS cell lines revealed that furin activity is required for proper processing of various cancer-related substrates, including IGF1R and MMP14, and that furin promotes motility and invasiveness in vitro as well as tumour growth in vivo. 52 Induced furin silencing reduces cell viability in all investigated RMS cell lines of the alveolar subtype, whereby half of all the cell lines are particularly sensitive-furin withdrawal leads to apoptosis induction and tumour regression. 53 Thus, furin appears to be a promising new target for treatment of paediatric rhabdomyosarcoma. Investigations on furin in other sarcoma types have been rather sparse. Nevertheless, application of furin inhibitors impairs MMP14 processing and reduces invasive capabilities of fibrosarcoma and osteosarcoma cell lines in vitro.
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Cancers of the brain and the central nervous system
First studies have shown that furin activity might promote the malignant phenotype of cancers of the brain and the central nervous system. Moderate to high furin expression is found in six out of eight high grade astrocytomas. 56 Inhibition of furin through use of the inhibitor PDX in astrocytoma cells leads to impaired processing of the known furin substrates IR (insulin receptor), TGFb and MMP14 in vitro and reduced cell proliferation, invasiveness and tumour size in vivo. 56 In glioma cells, BCL-2-or hepatocyte growth factor (HGF aka scatter factor or SF)-induced enhanced furin activity promotes invasiveness of the cells in vitro; accordingly the invasive phenotype can be rescued through inhibition of furin. 57 
Skin cancers
Extensive investigations on furin in skin cancer are rather sparse, nevertheless a few studies have indicated that furin might play a role in skin SCC formation. Transgenic mice with enhanced furin expression targeted to the epidermal basal layer develop twice as many SCC of the skin than control mice upon application of a two-stage carcinogenesis protocol and occurring SCC are more likely to be of high grade. 58 Furthermore, these mice are more susceptible to UV radiation-induced formation of skin SCC, whereby additional overexpression of PCSK6 did not affect tumour incidence, but enhanced tumour histopathologic grade. 59 These latter results indicate that in certain cases PCs can operate conjointly to drive tumour progression.
Furin Cleaves Cancer-Related Proproteins
Furin and furin-like PCs process a variety of substrates including various intracellular and extracellular eukaryotic proproteins, but also pathogen-derived proproteins like the fusion glycoprotein of measles virus. 60 ). In this section we will highlight a few known cancer-related furin substrates that have been shown to promote cellular processes important for the malignant phenotype of cancer cells (Fig. 1) . 
Growth factors and their receptors
Many cancer types are known to depend on growth factor signalling pathways for maintaining certain malignant characteristics such as unrestricted proliferation and high invasive potential. Various growth factors and their receptors involved in these processes require proteolytic activation by PCs to be converted into their mature forms. For instance, IGF1R as well as its ligand IGF1 are processed by furin-like PCs. 50, 63 Likewise, the activity of furin, PCSK5B or PCSK6 seems to be necessary to process the precursor of the neurotrophin nerve growth factor (NGF). 64 74 Interestingly, pro-MMP2 may also be cleaved intracellular 75 likely by furin. 76 However, the resulting secreted protein appears to be inactive and Cao et al. hypothesised that this provides a paradoxical regulatory mechanism to control MMP14-mediated activation of pro-MMP2. 76 Apart from MMP14, furin also cleaves other members of the membrane-type MMPs. For instance, furin activity appears to mediate cleavage of MMP16 (aka MT3-MMP) within the TGN 77 and shedding of MMP24
(aka MT5-MMP). 78 Further metalloproteases involved in ECM degradation are synthesised as inactive zymogens and appear to require cleavage through furin or furin-like PCs in order to gain their full activity. These comprise for example stromelysin-3, 79,80 the secreted ADAMTS-1 (a disintegrin and metalloprotease with thrombospondin motif 1) 81 and the adamalysin metalloproteases ADAM12 82 and ADAM17, 83 the latter of which is also known as tumour necrosis factor a convertase (TACE). Recently, it has been shown that irradiation induced furin-mediated activation of ADAM17 in NSCLC cells, resulting in shedding of survival factors. 84 
Cell adhesion molecules
Cell adhesion molecules (CAMs) are proteins that are present on the cell surface and mediate cell-cell or cell-matrix interactions. Furthermore, integrins are involved in the activation of cell survival and proliferation mechanisms. In the context of metastasis formation, CAMs play a pivotal role in migration and invasion of a tumour cell through lymphatic or angiogenic vessels as well as in arrest and extravasation of the cell at a distal site. The activity of furin-like PCs has been implicated in the activation of integrin a-subunits. Half of the known a-subunits contain potential PC processing sites and a3, a4, a5. a6 and av have been shown to be cleaved by furin. [85] [86] [87] Furin also appears to process two cadherins: Ecadherin 88 and N-cadherin. 89, 90 Activation of selectins and immunoglobins on the other hand appears to be only indirectly favoured by furin activity. For instance, some known furin substrates like IGF1 and endothelin promote expression of the immunoglobins ICAM-1 (intercellular adhesion molecule 1) and VCAM-1 (vascular cell adhesion protein 1). 91, 92 Angiogenic and lymphangiogenic factors Efficient tumour growth requires sufficient supply of oxygen and nutrients, highlighting the importance of adequate vascularisation. It could be shown that VEGF-C and VEGF-D have to be fully processed by furin or related PCs to stimulate VEGF signalling and induce angiogenesis and lymphangiogenesis. 93, 94 Additionally, only mature VEGF-C appears to be able to initiate tumourigenesis in mice. 95 Similarly, PDGF-A and PDGF-B require processing through furin to exert their diverse functions. 66, 67 For instance, PDGF-B favours tumour angiogenesis through paracrine stimulation of its receptor PDGFR-b, and subsequent induction of endothelial cell proliferation, migration and sprouting. 96 Furthermore, autocrine PDGF signalling increases the metastatic potential of breast cancer and pancreatic cancer cells. 97, 98 In diverse studies it has been shown that class III semaphorins are cleaved by furin or furin-like PCs, sometimes at multiple sites, [99] [100] [101] [102] however, the functional consequences of the processing step vary among the different members of this family. Proteolytic processing of Sema3F is a prerequisite for anti-angiogenic activity as it enables its binding to neuropilin receptors and thus blocks binding of VEGF. 102 In contrast, cleavage of Sema3B inactivates its repellent effect on endothelial cells. 101 Similarly, processing of Sema3E disables the antiangiogenic activity of this cytokine and even converts it into a potent inducer of invasive growth in mammary adenocarcinoma cells. 100 Mutated, uncleavable Sema3E is an inhibitor of tumour angiogenesis and growth in multiple tumour models, demonstrating its therapeutic potential. 103 
Furin Is a Tool for Cancer Cell-Specific Therapeutic Approaches
Aberrant furin activity in cancer cells offers the possibility to target this protease for anti-cancer therapy. A review of patent applications based on furin or furin inhibitors has been published recently by Couture et al. 104 Here, we will highlight a few chosen, novel furin-based approaches for cancer therapy (Fig. 2) . These approaches range from inhibition of furin to immunomodulatory therapy and use of furin as a target receptor or probe-activating enzyme.
Inhibition or Silencing of Furin
Based on furin's key role in promoting the malignant phenotype of cancer cells furin-specific inhibitors might be employed to inhibit the processing of cancer-related furin substrates. To our knowledge, the only reported furin-specific inhibitors are camelide antibodies, which were shown to inhibit processing of bulky protein substrates in a non-competitive manner. 105, 106 As furin is a ubiquitously expressed enzyme, furin-specific inhibitors would have to be evaluated carefully. Potential side effects arising from inhibition of furin in off-target tissue might be compensated for by activity of other furin-like PCs, like PCSK5, PCSK6 or PCSK7, which have a partially redundant function in cleaving proproteins. 107 In very recent years Senzer et al. described for the first time the development of an autologous cancer cell vaccine that is partly based on silencing of furin. 108 This furin-knockdown and GM-CSF (granulocyte-macrophage colony-stimulating factor)-augmented (FANG) cancer vaccine is based on the genetic modification and reinjection of patient-derived cancer cells to elicit an anti-tumoural immune response. Silencing of furin is employed to inhibit maturation of the immunosuppressive cytokine TGFb1. Safety of the FANG vaccine and efficacy of the immune response were confirmed and benefits of treatment were suggested by phase I and II trials in patients with advanced cancers including Ewing sarcoma, hepatocellular carcinoma and ovarian cancer. [109] [110] [111] [112] Furin as a target receptor and probe-activating enzyme Alternatively to inhibition or silencing of furin, furin might be used as a tool for delivery or tumour site-specific activation of therapeutic compounds. Cell surface furin has been shown to be a potential target receptor for rhabdomyosarcoma homing peptides. 113 These cancer-targeting peptides might further be explored for tumour cell-specific delivery of chemotherapeutics. Other approaches use furin-mediated endoproteolytic cleavage of immunotoxins for intracellular activation of toxins. These recombinant immunotoxins are hybrid proteins composed of toxins linked to targeting molecules, for example, monoclonal antibodies. For instance, the immunotoxin SS1P targets mesothelin-positive cancer cells and delivers toxic fragments of Pseudomonas exotoxin A upon endocytosis and cleavage through intracellular furin. 114 Another example is the use of immune-tBid targeting human epidermal growth factor receptor 2 (ERBB2 aka HER2)-positive tumours, which, similar to SS1P, contains a furincleavable linker sequence. 115 Similar furin-cleavable linkers increased the uptake of receptor-targeted nanocomplex formulations, which have been proposed for tumour-specific gene transfer. 116 The proteolytic activity of furin can also be exploited for improved tumour imaging through the use of furin activatable imaging probes. For instance, Dragulescu-Andrasi et al. described furin-activatable photoacoustic and bioluminogenic probes and demonstrated their usefulness for furin activitydependent visualisation of breast cancer xenografts. 117, 118 Furthermore, furin has been demonstrated to cleave "smart" imaging agents. Thus, furin-induced cleavage leads to condensation and self-assembly of gadolinium-based or radioactivelabelled nanoparticles, which might be used for tumourspecific magnetic resonance imaging (MRI) or positron emission tomography (PET), respectively.
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Conclusions
In recent years the expression pattern and role of furin has been studied in various cancer types, including carcinomas, sarcomas, skin cancers as well as tumours of the brain or central nervous system. In most cases furin activity correlates with increased aggressiveness of cancers. However, we would like to mention that in certain instances furin might actually have a repressive effect on cancer cells. 121, 122 Due to its cancer-promoting role, furin represents an interesting target for therapeutic intervention. Thus, furin inhibition might be beneficial for treatment of a variety of cancers. However, specificity for furin is limited for most reported furin inhibitors as they likewise inhibit other structurally related furin-like PCs. This might elicit unwanted toxic effects upon use in clinical settings. Furthermore, as varying levels of furin expression have been reported in various tissues the therapeutic index and potential systemic toxicities have to be carefully evaluated in preclinical studies.
Alternatively, a very promising approach is the downregulation of furin expression by use of antisense technology, as it is employed for manufacturing of the FANG vaccine. In Figure 2 . Furin as a tool for cancer-specific therapeutic approaches. Overview of key therapeutic approaches exploiting aberrant furin activity in cancer cells, and one representative example.
the case of the FANG vaccine the risk of adverse systemic reactions is rather low due to tumour cell-specific furin silencing ex vivo. The efficacy of this immunomodulatory anticancer approach has been demonstrated in early clinical trials and we are looking forward to seeing long-term study results in the future.
Apart from inhibition or silencing of furin, aberrant furin activity in cancer cells might be exploited for alternative approaches such as cancer site-directed activation of immunotoxins or imaging agents or tumour targeting by use of furinspecific binding peptides. As in the case of furin inhibitors, extensive preclinical trials will be required to determine the therapeutic index and to avoid occurrence of unwanted adverse reactions based on furin expression in non-target tissue.
In conclusion, detailed investigations conducted over the last two decades have shown that furin represents a valuable target for cancer therapy. Future studies will likely lead to expansion of our knowledge on the role of furin in further cancer types and will improve and expand the repertoire of furin targeted therapies, ranging from furin inhibition, immunomodulatory therapy to tumour site-specific activation of toxins or imaging agents.
